FGFR2 as a molecular target in endometrial cancer (Q37401322)

20 August 2017

1 reference

title

FGFR2 as a molecular target in endometrial cancer (English)

1 reference

20 August 2017

Sara A Byron

1

0 references

Pamela M. Pollock

object named as

Pamela M Pollock

series ordinal

2

0 references

language of work or name

English

0 references

publication date

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

1

1 reference

20 August 2017

27-32

1 reference

Surgery followed by radiotherapy in endometrial cancer: analysis of survival and patterns of failure.

20 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Fibroblast growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Structural basis for fibroblast growth factor receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

FGFs, their receptors, and human limb malformations: clinical and molecular correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Expression cDNA Cloning of the KGF Receptor by Creation of a Transforming Autocrine Loop

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Molecular and pathologic aspects of endometrial carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

Aurora kinases and their inhibitors: more than one target and one drug

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.27

21 January 2018

Identifiers

DOI

10.2217/14796694.5.1.27

1 reference

20 August 2017

1 reference

PubMed ID

19243295